BioNTech SE (BioNTech SE) Other Gross PPE : $380 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is BioNTech SE Other Gross PPE?

BioNTech SE's Other Gross PPE for the quarter that ended in Dec. 2023 was $380 Mil.

BioNTech SE's quarterly Other Gross PPE increased from Jun. 2023 ($969 Mil) to Sep. 2023 ($988 Mil) but then declined from Sep. 2023 ($988 Mil) to Dec. 2023 ($380 Mil).

BioNTech SE's annual Other Gross PPE increased from Dec. 2021 ($250 Mil) to Dec. 2022 ($295 Mil) and increased from Dec. 2022 ($295 Mil) to Dec. 2023 ($380 Mil).

BioNTech SE Other Gross PPE Historical Data

The historical data trend for BioNTech SE's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Other Gross PPE Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

92.46

182.00

249.83

294.92

380.26

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Gross PPE	Get a 7-Day Free Trial															294.92	907.50	968.58	988.15	380.26

BioNTech SE Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

BioNTech SE (BioNTech SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (NAS:BNTX) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil BNTX:Austria

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.